BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30580099)

  • 1. Identification of a novel function of hepatic long-chain acyl-CoA synthetase-1 (ACSL1) in bile acid synthesis and its regulation by bile acid-activated farnesoid X receptor.
    Singh AB; Dong B; Xu Y; Zhang Y; Liu J
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):358-371. PubMed ID: 30580099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SREBP2 Activation Induces Hepatic Long-chain Acyl-CoA Synthetase 1 (ACSL1) Expression in Vivo and in Vitro through a Sterol Regulatory Element (SRE) Motif of the ACSL1 C-promoter.
    Singh AB; Kan CF; Dong B; Liu J
    J Biol Chem; 2016 Mar; 291(10):5373-84. PubMed ID: 26728456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
    Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
    Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis.
    Ling CJ; Xu JY; Li YH; Tong X; Yang HH; Yang J; Yuan LX; Qin LQ
    Food Funct; 2019 Nov; 10(11):7299-7307. PubMed ID: 31626262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice.
    Massafra V; Milona A; Vos HR; Ramos RJJ; Gerrits J; Willemsen ECL; Ramos Pittol JM; Ijssennagger N; Houweling M; Prinsen HCMT; Verhoeven-Duif NM; Burgering BMT; van Mil SWC
    Gastroenterology; 2017 May; 152(6):1462-1476.e10. PubMed ID: 28130067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
    Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency of Both Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice.
    Ferrell JM; Pathak P; Boehme S; Gilliland T; Chiang JYL
    Hepatology; 2019 Sep; 70(3):955-970. PubMed ID: 30664797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol-lowering effects of taurine through the reduction of ileal FXR signaling due to the alteration of ileal bile acid composition.
    Miyata M; Tanaka T; Takahashi K; Funaki A; Sugiura Y
    Amino Acids; 2021 Oct; 53(10):1523-1532. PubMed ID: 34596761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
    Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
    Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model.
    Kunne C; Acco A; Duijst S; de Waart DR; Paulusma CC; Gaemers I; Oude Elferink RP
    Biochim Biophys Acta; 2014 May; 1842(5):739-46. PubMed ID: 24548803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-specific knockdown of long-chain acyl-CoA synthetase 4 reveals its key role in VLDL-TG metabolism and phospholipid synthesis in mice fed a high-fat diet.
    Singh AB; Kan CFK; Kraemer FB; Sobel RA; Liu J
    Am J Physiol Endocrinol Metab; 2019 May; 316(5):E880-E894. PubMed ID: 30721098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase.
    Matsukuma KE; Bennett MK; Huang J; Wang L; Gil G; Osborne TF
    J Lipid Res; 2006 Dec; 47(12):2754-61. PubMed ID: 16957179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of essential fatty acid deficiency on enterohepatic circulation of bile salts in mice.
    Lukovac S; Los EL; Stellaard F; Rings EH; Verkade HJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G520-31. PubMed ID: 19608735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
    Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
    PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition.
    Li LO; Ellis JM; Paich HA; Wang S; Gong N; Altshuller G; Thresher RJ; Koves TR; Watkins SM; Muoio DM; Cline GW; Shulman GI; Coleman RA
    J Biol Chem; 2009 Oct; 284(41):27816-27826. PubMed ID: 19648649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.
    Singh AB; Dong B; Kraemer FB; Liu J
    Physiol Rep; 2020 Mar; 8(5):e14387. PubMed ID: 32170842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.